Personalized mRNA vaccine shows promise in fighting melanoma return
NCT ID NCT03897881
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma that has been completely removed. The vaccine is custom-made for each patient based on their tumor's genetic profile, aiming to train the immune system to recognize and attack any remaining cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affinity Clinical Research
Murdoch, Western Australia, 6150, Australia
-
Angeles Clinic and Research Institute
Santa Monica, California, 90404, United States
-
California Pacific Medical Center Research Institute -CPMCRI
San Francisco, California, 94115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Melanoma Institute Australia
North Sydney, New South Wales, 2060, Australia
-
NYU Langone Medical Center
New York, New York, 10016, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
One Clinical Research Perth
Murdoch, Western Australia, 6150, Australia
-
Orlando Health UF Health Cancer Center
Orlando, Florida, 32806, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
-
Smilow Cancer Center at Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
-
St John of God Hospital Subiaco
Subiaco, Western Australia, 6008, Australia
-
Texas Oncology PA
Dallas, Texas, 75246, United States
-
UPMC Hillman Cancer Center
Chicago, Illinois, 60637, United States
-
University of Arizona
Tucson, Arizona, 85719, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized mRNA cancer vaccine (mRNA-4157) and pembrolizumab
What this could lead to
If successful, this could offer a more effective way to prevent melanoma from coming back after surgery, potentially improving long-term survival.
What could go wrong
This is an early phase 2 trial with only 267 participants, so results may not apply to everyone. The vaccine is personalized, which makes it complex and expensive, and there is no guarantee it will outperform standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.